Demographics for the cohort of patients who received HSCT; including primary diagnosis, HLA molecular typing, transplant conditioning regimen, and GVHD prophylaxis
| . | Total . | GVHD . | No GVHD . | P . |
|---|---|---|---|---|
| No. | 17 | 9 | 8 | |
| Age at transplant, y | ||||
| Median (q25-q75) | 11 (7.5-14.5) | 11 (6.5-14.5) | 13 (8.7-16.25) | .41 |
| Sex (M, %) | 8 (47.1) | 4 (44) | 4 (50) | .97 |
| Primary diagnosis | ||||
| ALL (%) | 6 (35) | 5 (55.6) | 1 (12.5) | .19 |
| AML (%) | 5 (29.5) | 2 (22.2) | 3 (37.5) | .45 |
| MDS (%) | 2 (11.7) | 1 (11.1) | 1 (12.5) | .99 |
| Severe aplastic anemia (%) | 2 (11.7) | 0 (0) | 2 (25) | .17 |
| Other (%) | 2 (11.7) | 1 (11.1) | 1 (12.5) | .93 |
| HLA molecular typing | ||||
| Matched related | 3 (17.6) | 3 (33.3) | 0 (0) | .16 |
| Matched unrelated | 0 (0) | 0 (0) | 0 (0) | NA |
| Mismatched related | 9 (53) | 4 (44.4) | 5 (62.5) | .89 |
| Mismatched unrelated | 5 (29.4) | 2 (22.2) | 3 (37.5) | .76 |
| Patient CMV serostatus | ||||
| Positive (%) | 2 (11.7) | 2 (22.2) | 0 (0) | .39 |
| GVHD prophylaxis | ||||
| αβ T-cell depletion | 8 (47.1) | 4 (44.4) | 4 (50) | .97 |
| Tacro, MTX | 3 (17.6) | 3 (33.3) | 0 | .21 |
| Tacro, MMF | 5 (29.4) | 2 (22.2) | 3 (37.5) | .22 |
| CsA, Tacro, MMF | 1 (5.9) | 0 | 1 (12.5) | .58 |
| Conditioning regimen | ||||
| Low-dose TBI (≤4 Gy) | 7 | 3 (33.3) | 4 (50) | .8 |
| High-dose TBI (≥10 Gy) | 10 | 6 (66.6) | 4 (50) | .78 |
| rATG | 12 | 6 (66.6) | 6 (75) | .93 |
| Thiotepa/fludarabine | 9 | 5 (55.6) | 4 (50) | .58 |
| Melphalan/clofarabine | 2 | 2 (22.2) | 0 | NA |
| Busulfan | 1 | 1 (11.1) | 0 | NA |
| Fludarabine/cyclophosphamide | 3 | 0 | 3 (37.5) | NA |
| Melphalan/thiotepa/clofarabine | 1 | 0 | 1 (12.5) | NA |
| . | Total . | GVHD . | No GVHD . | P . |
|---|---|---|---|---|
| No. | 17 | 9 | 8 | |
| Age at transplant, y | ||||
| Median (q25-q75) | 11 (7.5-14.5) | 11 (6.5-14.5) | 13 (8.7-16.25) | .41 |
| Sex (M, %) | 8 (47.1) | 4 (44) | 4 (50) | .97 |
| Primary diagnosis | ||||
| ALL (%) | 6 (35) | 5 (55.6) | 1 (12.5) | .19 |
| AML (%) | 5 (29.5) | 2 (22.2) | 3 (37.5) | .45 |
| MDS (%) | 2 (11.7) | 1 (11.1) | 1 (12.5) | .99 |
| Severe aplastic anemia (%) | 2 (11.7) | 0 (0) | 2 (25) | .17 |
| Other (%) | 2 (11.7) | 1 (11.1) | 1 (12.5) | .93 |
| HLA molecular typing | ||||
| Matched related | 3 (17.6) | 3 (33.3) | 0 (0) | .16 |
| Matched unrelated | 0 (0) | 0 (0) | 0 (0) | NA |
| Mismatched related | 9 (53) | 4 (44.4) | 5 (62.5) | .89 |
| Mismatched unrelated | 5 (29.4) | 2 (22.2) | 3 (37.5) | .76 |
| Patient CMV serostatus | ||||
| Positive (%) | 2 (11.7) | 2 (22.2) | 0 (0) | .39 |
| GVHD prophylaxis | ||||
| αβ T-cell depletion | 8 (47.1) | 4 (44.4) | 4 (50) | .97 |
| Tacro, MTX | 3 (17.6) | 3 (33.3) | 0 | .21 |
| Tacro, MMF | 5 (29.4) | 2 (22.2) | 3 (37.5) | .22 |
| CsA, Tacro, MMF | 1 (5.9) | 0 | 1 (12.5) | .58 |
| Conditioning regimen | ||||
| Low-dose TBI (≤4 Gy) | 7 | 3 (33.3) | 4 (50) | .8 |
| High-dose TBI (≥10 Gy) | 10 | 6 (66.6) | 4 (50) | .78 |
| rATG | 12 | 6 (66.6) | 6 (75) | .93 |
| Thiotepa/fludarabine | 9 | 5 (55.6) | 4 (50) | .58 |
| Melphalan/clofarabine | 2 | 2 (22.2) | 0 | NA |
| Busulfan | 1 | 1 (11.1) | 0 | NA |
| Fludarabine/cyclophosphamide | 3 | 0 | 3 (37.5) | NA |
| Melphalan/thiotepa/clofarabine | 1 | 0 | 1 (12.5) | NA |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CMV, cytomegalovirus; CsA, cyclosporin A; M, male; MMF, Mycophenolate mofetil; MDS, myelodysplastic syndrome; MTX, Methotrexate; rATG, rabbit anti-thymocyte globulin; q25-q75, (25th-75th quartile); Tacro, Tacrolimus.